The fact that second-generation AR-directed drugs (e.g., enzalutamide, abiraterone) confer survival benefits to patients with CRPC underscores the persistent dependence of most PCa on the AR axis, even after ADT failure [30]. This evidence concerns the gene AR and posterior cortical atrophy.